post better expect ebitda revenu biopharma result strong
surpris upsid reproduct medicin segment anim
health fell short rel estim remain encourag continu
scale busi open two new facil maintain pt
outperform rate
beat ebitda adjust stock-bas compens estim post
vs street report ep
line estim slightli better consensu
post revenu beat estim street
caus beat strong perform biotech
segment beat estim coupl beat
reproduct medicin segment partial off-set miss anim health
segment experienc fluctuat revenu recent quarter
compani gener commerci revenu quarter car-t
therapi kymriah novarti yescarta gilead nearli sequenti
continu ramp higher therapi grow marketplac
first two commerci therapi support gone smoothli
thu far given infanc car-t marketplac compani success support
therapi paramount
slight gross margin contract quarter report margin
come estim howev open irvin california-
base compani two new facil livingston new jersey amsterdam
netherland quarter understand up-front cost relat two rollout
like caus slight margin contract remain construct
compani abil expand margin come quarter year
product help asset-light model becom even asset-light add total
non-asset financi servic product offer
quarter rais number biopharma trial across three phase
sequenti phase trial rose phase phase
number commerci client remain time
believ quarter confirm posit continu take
advantag spread car-t therapi around world along drug
adjust ebitda estim slightli account
strong ebitda quarter off-set slightli lower margin expect
continu appli multipl ebitda estim
maintain price target
pleas see page report import disclosur
like benefit next sever year commerci new
therapi compani like gilead/kit novarti juno play vital role
logist potenti life-sav biopharma treatment patient certain
form cancer
growth number trial
start juno pivot trial
blue/celg start pivot trial
help gilead/kit nv scale
commerci therapi
commerci therapi approv
fda approv
biopharma custom trial today
lead provid cold chain logist solut temperature-sensit
life scienc materi serv biopharmaceut ivf surrogaci anim health
organ around world cryoport proprietari cryoport express liquid nitrogen dri
monitor system geo-sens technolog pair cold chain expertis
custom support key element value-ad servic offer custom
use one-year forward pe multipl valu cover compani air freight
logist industri support valuat ev/ebitda tangibl book valu
primari freight logist industri risk
risk econom downturn potenti impact integr parcel busi
competit threat pose mode freight transport rail
risk busi abroad includ currenc exchang polit legal risk
risk terror cost associ stringent secur requir
compani custom experi advers result drug/therapi trial
unabl handl grow need biopharma logist servic addit could
increas number competitor market car-t cell therapi
regen medicin becom preval
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock canadian nation railway compani
jason seidl author research report elect presid north east associ rail shipper near rail transport industri group two-year term
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen credit research trade due natur fix incom market issuer debt secur issuer discuss cowen credit research trade
research report assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon
analysi reflect analyst opinion date report expect continu analysi addit report relat issuer debt secur
time time cowen credit research trade research analyst provid invest recommend secur subject report
recommend intend time date public within paramet specifi individu report cowen credit research trade
invest recommend made strictli case-by-cas basi recommend provid part overarch rate system set consist
appli benchmark view express report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc novemb et dissemin novemb et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
prohibit receipt and/or review research constitut agreement reproduc display modifi distribut transmit disclos other outsid organ
cowen trademark display report own cowen may use without prior written consent
cowen compani llc new york boston san francisco chicago cleveland atlanta
outperform stock expect achiev total posit return least next month
market perform stock expect total return fall paramet outperform under-perform next month
under-perform stock expect achiev total neg return least next month
cowen compani equiti research rate distribut
distribut ratings/invest bank servic ib
correspond outperform rate stock defin cowen compani llc equiti research rate definit correspond market perform defin cowen
compani llc equiti research rate definit correspond under-perform defin cowen compani llc equiti research rate definit cowen
compani equiti research rate distribut tabl includ compani equiti research rate current suspend debt secur follow cowen
credit research trade
note buy hold sell term cowen compani llc use rate system constru invest option rather rate term
use illustr compli finra regul
rate histori
power bluematrix
canadian nation railway compani rate histori
power bluematrix
rate histori
power bluematrix
rate histori
power bluematrix
legend price chart
jason seidl senior analyst focus
rail truck logist
year transport industri experi
part freight team
sinc previous cover
marc frahm analyst cover
biotechnolog join cowen
complet ph duke
